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Abstract It has recently been suggested that the concomitant
activation of two distinct G protein-coupled receptors (Gi and
Gq) is essential for platelet aggregation: in fact, the thrombox-
ane A2 synthetic agonist, U46619, which causes the selective
activation of Gq, is not able to elicit fibrinogen receptor exposure
unless ADP or epinephrine is present. In the present study we
demonstrate that a direct Gq activation is not required for
platelet aggregation and that the activation of an enzyme
downstream of Gq, such as phospholipase C (PLC) or protein-
kinase C (PKC), is sufficient for such a process. In fact, platelet
aggregation occurred in response to the snake venom toxin
convulxin, which activates the PLC isoform PLCQ2 or to
cytosolic PKC activator phorbol 12-myristate 13-acetate
(PMA) provided a Gi protein-coupled receptor was activated
by ADP or epinephrine. The evidence that the PKC inhibitor, Ro
31-8220 did not suppress platelet aggregation in response to
convulxin plus ADP or epinephrine led us to conclude that PLC
and PKC are both involved in platelet aggregation, although not
concomitantly, provided a Gi protein-coupled receptor is
activated.
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1. Introduction
The integrin KIIbL3-ligand interactions have been widely
studied due to their crucial role in the adhesive events critical
for primary hemostasis and formation of the hemostatic plug.
The ¢brinogen binding site on KIIbL3, which in resting plate-
lets is inaccessible to ¢brinogen, undergoes a conformational
change once platelets are stimulated, thus permitting the for-
mation of a stable aggregate. Many authors have tried to
identify the cell surface receptors involved in platelet aggrega-
tion and to de¢ne the downstream intracellular e¡ectors re-
sponsible for the exposure of the ¢brinogen binding site [1].
Recently, it has been suggested that the concomitant activa-
tion of two distinct G protein-coupled ADP receptors, one
(P2Y1) coupled to phospholipase C, involving Gq, and the
other (P2TAC) to inhibition of adenylyl cyclase, via a Gi-medi-
ated pathway [2] is essential for ADP-induced platelet aggre-
gation [3,4]. This is in agreement with the results of a previous
work in which we demonstrated that the thromboxane A2
synthetic agonist, U46619, which causes the selective activa-
tion of Gq [5], was not able to elicit ¢brinogen binding unless
ADP was released [6].
Subsequently, in order to con¢rm this theory, we performed
experiments on platelets treated with an ADP scavenger sys-
tem and stimulated with U46619 plus epinephrine, an agonist
which selectively activates the Gi protein and potentiates pla-
telet aggregation induced by other agonists acting via Gq [7,8].
The results demonstrated that the coactivation of Gi and Gq
was essential for U46619-induced platelet aggregation, and
did not require any increase in cytosolic calcium concentra-
tion [9].
Therefore, aim of the present study was to verify whether a
direct Gq activation is required for platelet aggregation or
whether a downstream enzyme activated by Gq, such as phos-
pholipase C (PLC) or protein-kinase C (PKC), is su⁄cient for
such a process.
For this purpose we used phorbol 12-myristate 13-acetate
(PMA) which is a cytosolic PKC activator, and convulxin, a
non-enzymic snake venom toxin from Crotalus durissus terri-
¢cus, which is a selective agonist of the collagen receptor
GpVI. This toxin activates the PLC isoform PLCQ2 and in-
duces tyrosine phosphorylation not requiring protein Gq acti-
vation and independently of integrin KIIbL3 [10,11].
Moreover, this study was aimed at better de¢ning the role
of ADP release reaction in platelet aggregation induced by
PMA and convulxin.
The results support the idea that the activation of PLC or
PKC is su⁄cient to cause platelet aggregation only in the
presence of a concomitant activation of a Gi protein-coupled
receptor.
2. Materials and methods
Blood samples were collected in acid/citrate/dextrose (ACD) from
informed healthy volunteers who denied having taken any drugs in
the 2 weeks prior to blood sampling. Platelet Rich Plasma (PRP) was
obtained after centrifugation (180Ug for 15 min) and then further
centrifuged (800Ug for 20 min) to concentrate the platelets (6U108
platelets/ml). The concentrated platelets were incubated for 15 min at
37‡C with 1 mM aspirin (Sigma, St. Louis, MO, USA) and then gel
¢ltered on Sepharose 2B-CL (Pharmacia, Uppsala, Sweden) using
Ca2-free Tyrode’s bu¡er containing 0.2% albumin (bovine serum
fraction V-BSA), 0.1% glucose and 10 mM HEPES (pH 7.35) (all
from Sigma).
In some experiments gel-¢ltered platelets (GFP) were treated with
the ADP scavenger system creatine phosphate/creatine kinase (CP/
CPK) (20 mM/ 50 U/ml) (Sigma) before the addition of the agonists.
Convulxin from Crotalus durissus terri¢cus (Latoxan, Rosans,
France) was puri¢ed according to Polgar et al. [11].
2.1. Platelet aggregation
In vitro platelet aggregation was evaluated according to Born in a
four sample PACKS-4 aggregometer (Helena Laboratories, Beau-
mont, TX, USA) using siliconized glass cuvettes at 37‡C under con-
tinuous stirring. Fibrinogen (1 mg/ml) (Sigma) was added before the
agonists.
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2.2. Changes in intracellular calcium concentrations
The changes in intracellular calcium concentrations were monitored
in gel-¢ltered platelets using the £uorescent dye Fura-2-AM (3 WM)
(Molecular Probes, Eugene, OR, USA) in response to convulxin (5 ng/
ml). The £uorescence changes were monitored with a Kontron SFM
25 £uorimeter, set at 340 nM excitation and 510 nM emission. Intra-
cellular free calcium was calibrated according to Grynkiewicz [12].
2.3. Preparation of BAPTA-treated platelets
The concentrated platelets were incubated for 30 min at 37‡C with
1 mM aspirin, 100 WM 1,2-bis (2-aminophenoxy) ethane-N,N,N,N-
tetra-acetic acid acetoxymethyl ester (BAPTA-AM) (Molecular
Probes). Excess BAPTA-AM was separated from the platelets by
gel-¢ltration. On each preparation the changes in intracellular calcium
concentrations were tested. In the presence of a vnM of Ca2 ob-
tained in response to convulxin higher than 10, the platelet suspension
was not used.
3. Results
In order to investigate the capability of convulxin and PMA
to induce platelet aggregation without the synergistic action of
the ampli¢cation mechanisms, all the experiments were per-
formed in the presence of aspirin. Moreover, in those experi-
ments in which a complete inhibition of ADP release was
required, the platelets were further treated with the ADP scav-
enger system creatine phosphate/creatine kinase (CP/CPK).
Fig. 1 shows platelet aggregation induced by convulxin
(5 ng/ml) in control (a) and in CP/CPK (20 mM and 50 U/
ml, respectively) treated platelets, subsequently stimulated
with epinephrine (5 WM) (b). The results show that convulxin
is not able to induce platelet aggregation, monitored for at
least 5 min (data not shown), in platelets in which released
ADP was removed by the scavenger system CP/CPK, unless
low concentrations of epinephrine (5 WM), unable per se to
cause any aggregometric response, were added.
Fig. 2 shows PMA-induced (10 WM) platelet aggregation in
control (a) and CP/CPK treated platelets, to which epineph-
rine (5 WM) (b) was added. The results show that platelet
aggregation in response to PMA is dependent on the ADP
released by the granules, as demonstrated by the fact that CP/
CPK treatment prevented the aggregation that was restored
only by the addition of the second agonist.
In order to discriminate the di¡erent roles played by PKC
and PLC in this process we employed the selective inhibitor of
PKC Ro 31-8220. In this experimental model the use of CP/
CPK was not required, as a total inhibition of the degranu-
lation was achieved with Ro 31-8220 alone [6].
Fig. 3 shows the aggregometric patterns of platelets treated
with Ro 31-8220 (10 WM), activated with convulxin (5 ng/ml),
plus epinephrine (5 WM) or ADP (5 WM). The results demon-
strate that both epinephrine and ADP are able to induce
Fig. 1. Platelet aggregation in aspirin-treated (1 mM) gel-¢ltered
platelets in response to convulxin (5 ng/ml) alone (a) or plus epi-
nephrine (5 WM) in the presence of the ADP scavenger system CP/
CPK (20 mM/50 U/ml) (b). The ¢gure is representative of ¢ve ex-
periments performed.
Fig. 2. Platelet aggregation patterns in aspirin-treated (1 mM) gel-
¢ltered platelets in response to PMA (10 WM) alone (a) or in combi-
nation with epinephrine (5 WM) in the presence of the ADP scav-
enger system CP/CPK (20 mM/50 U/ml) (b). The ¢gure is represen-
tative of ¢ve experiments performed.
Fig. 3. Platelet aggregation patterns in response to convulxin (5 ng/
ml) plus ADP (5 WM) (a) or epinephrine (5 WM) (b) in aspirin-, Ro
31-8220-treated (1 mM and 10 WM respectively) gel-¢ltered platelets.
The ¢gure is representative of ¢ve experiments performed.
Fig. 4. Changes in intracellular calcium concentrations in control
(a), CP/CPK treated (20 mM/50 U/ml) (b) and Ro 31-8220 treated
(10 WM) (c) Fura-2 loaded gel-¢ltered platelets in response to con-
vulxin (5 ng/ml). The ¢gure is representative of ¢ve experiments per-
formed.
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platelet aggregation synergistically with convulxin through
biochemical events independent of protein-kinase C activa-
tion. In the presence of Ro 31-8220 no aggregometric re-
sponse to ADP stimulation was observed (data not shown).
As expected, in the presence of PKC inhibition, PMA
proved unable to induce platelet aggregation in spite of epi-
nephrine or ADP addition (data not shown).
Fig. 4 reports the changes in intracellular calcium concen-
trations in convulxin-stimulated platelets in the presence or
absence of the ADP scavenger system CP/CPK or of the
PKC inhibitor Ro 31-8220. The results show that convulxin
was able to induce an appreciable increase in cytosolic calci-
um concentrations (trace a), that was not modi¢ed by the
treatment with CP/CPK (b) or Ro 31-8220 (c).
As in a previous work we demonstrated that a calcium
chelator, BAPTA, did not cause any inhibition of platelet
aggregation in response to U46619 plus ADP or epinephrine
[9], we tested the role of calcium in convulxin- and PMA-
induced platelet aggregation.
Fig. 5 shows the aggregometric patterns of BAPTA-treated
platelets in response to convulxin (5 ng/ml) followed by the
addition of epinephrine (5 WM) or ADP (5 WM). The results
demonstrate that convulxin was able to cause platelet aggre-
gation only if the degranulation reaction, with the subsequent
release of endogenous ADP, took place; in fact, the addition
of ADP or epinephrine to convulxin-stimulated platelets gave
rise to a maximal aggregation.
In this process PKC activation does not seem an essential
prerequisite, even in the absence of calcium. In fact, when
BAPTA-treated platelets were incubated with the PKC inhib-
itor Ro 31-8220 (10 WM) (Fig. 6) before the stimulation with
convulxin, a relevant response was obtained after the addition
of epinephrine or ADP.
Comparable results were obtained when PMA was used as
an agonist (Fig. 7).
4. Discussion
Platelet aggregation requires the concomitant activation of
two G-protein coupled receptors, Gi and Gq [3,4,9]. In a pre-
vious work we demonstrated that the synthetic agonist of
thromboxane A2 receptor U46619, which activates Gq pro-
tein, was per se unable to cause platelet aggregation without
the concomitant activation of a Gi protein coupled receptor
induced by ADP or epinephrine [5,8]. Gi activation is inde-
pendent of reduction of cyclic AMP concentration, as dem-
onstrated by the fact that platelets pre-treated with the adeny-
late cyclase inhibitor SQ 22536 failed to aggregate in response
to U46619 alone [9].
The results shown in this paper demonstrate that a pathway
downstream of Gq activation is able to cause the conforma-
tional changes in the integrin KIIbL3 responsible for platelet
aggregation, provided a Gi protein coupled receptor is also
activated. In fact, by selectively activating the isoform of
phospholipase C PLCQ2, with the snake venom convulxin,
which is independent of Gq protein, but dependent on tyro-
sine kinase activation [10,11], we observed a platelet activation
similar to that obtained in response to U46619. Gel-¢ltered
Fig. 5. Platelet aggregation patterns in response to convulxin (5 ng/
ml) in combination with ADP (5 WM) (a) or epinephrine (5 WM) (b)
in aspirin-, BAPTA-treated (1 mM and 100 WM respectively) plate-
lets. The ¢gure is representative of ¢ve experiments performed.
Fig. 6. Platelet aggregation patterns in response to convulxin (5 ng/
ml) in combination with ADP (5 WM) (a) or epinephrine (5 WM) (b)
in aspirin-, BAPTA-treated (1 mM and 100 WM, respectively) plate-
lets incubated with Ro 31-8220 (10 WM). The ¢gure is representative
of ¢ve experiments performed.
Fig. 7. Platelet aggregation patterns in response to PMA (10 WM)
plus ADP (5 WM) (a) or epinephrine (5 WM) (b) in aspirin-, BAP-
TA-treated (1 mM and 100 WM respectively) platelets. The ¢gure is
representative of ¢ve experiments performed.
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platelets aggregated in response to convulxin only in the pres-
ence of ADP released from platelet granules. When ADP was
removed by means of the scavenger system CP/CPK, an ap-
preciable aggregometric response was achieved only when a
Gi protein coupled receptor, like the K2-adrenergic receptor,
was rapidly activated [7,8].
Platelet pre-treatment with CP/CPK did not inhibit platelet
activation induced by convulxin, as demonstrated by the ob-
servation that such treatment did not modify the changes in
intracellular calcium concentrations. These results led us to
hypothesize that the activation of PLC or other biochemical
pathways triggered by the Gq protein are responsible for
platelet aggregation.
The initial hypothesis conferring to protein kinase C acti-
vation the role of key step in Gi protein dependent platelet
aggregation was based on the observation that the cytosolic
protein kinase C activator PMA behaved in the same manner
as U46619 and convulxin, requiring epinephrine or ADP to
induce platelet aggregation. On the contrary, platelet treat-
ment with the protein kinase C inhibitor Ro 31-8220 failed
to inhibit the synergistic response of convulxin plus ADP or
epinephrine. This datum is in agreement with previous obser-
vations indicating that Ro 31-8220 did not modify the aggre-
gometric response to U46619 plus ADP or to thrombin alone
[6,13]. From our results we can thus conclude that both phos-
pholipase C and protein kinase C are required for platelet
aggregation, although their concomitant activation is not nec-
essary. Moreover, the pathway involved in this process is not
dependent on calcium concentration, as platelet treatment
with the cytosolic calcium chelator BAPTA did not inhibit
the aggregometric response to the combined stimulation by
convulxin or PMA plus ADP or epinephrine. Besides, in
this platelet preparation, PLC activation was su⁄cient to in-
duce a complete aggregation in response to convulxin plus
ADP or epinephrine and did not require the concomitant
activation of PKC, as demonstrated by the fact that the pro-
tein kinase C inhibitor Ro 31-8220 failed to inhibit this re-
sponse.
From all our data we can conclude that PLC and PKC are
both involved in inducing platelet aggregation, their concom-
itant activation not being necessary, provided a Gi protein-
coupled receptor is activated.
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